Diligence memo · auto-generated · as of July 3, 2026
ONDINE BIOPHARMA Corp
ONDINE BIOPHARMA Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
ONDINE BIOPHARMA Corp operates in Biotechnology, based in VANCOUVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ONDINE BIOPHARMA Corp has raised $719K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $480K on 2009-12-07.
Most recent recorded round closed around 2009-12-23.
Valuation (modeled)modeled
Provath models ONDINE BIOPHARMA Corp at approximately $13M (range $128K–$150M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.48× the median modeled value of Pre-Seed Biotechnology companies in 2007–2009 (62 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 16.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 14% of Biotechnology peers (4293 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Cellay, Inc., Cellutions Inc, Atherotech, Inc., Bio-Tree Systems, Inc., Theocorp Holding Company, LLC.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.